NASDAQ:JAGX Jaguar Animal Health (JAGX) Stock Price, News & Analysis $1.63 +0.03 (+1.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.86%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Jaguar Animal Health Stock (NASDAQ:JAGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Jaguar Animal Health alerts:Sign Up Key Stats Today's Range$1.57▼$1.6850-Day Range$1.60▼$3.0552-Week Range$1.57▼$35.25Volume102,798 shsAverage Volume137,111 shsMarket Capitalization$3.54 millionP/E RatioN/ADividend YieldN/APrice Target$60.00Consensus RatingBuy Company Overview Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. Read More Jaguar Animal Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreJAGX MarketRank™: Jaguar Animal Health scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJaguar Animal Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageJaguar Animal Health has received no research coverage in the past 90 days.Read more about Jaguar Animal Health's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jaguar Animal Health are expected to decrease in the coming year, from ($0.80) to ($2.06) per share.Price to Book Value per Share RatioJaguar Animal Health has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Jaguar Animal Health's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.77% of the float of Jaguar Animal Health has been sold short.Short Interest Ratio / Days to CoverJaguar Animal Health has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jaguar Animal Health has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJaguar Animal Health does not currently pay a dividend.Dividend GrowthJaguar Animal Health does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.77% of the float of Jaguar Animal Health has been sold short.Short Interest Ratio / Days to CoverJaguar Animal Health has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jaguar Animal Health has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News SentimentN/A News SentimentJaguar Animal Health has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Jaguar Animal Health this week, compared to 1 article on an average week.Search Interest2 people have searched for JAGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jaguar Animal Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.55% of the stock of Jaguar Animal Health is held by insiders.Percentage Held by InstitutionsOnly 12.04% of the stock of Jaguar Animal Health is held by institutions.Read more about Jaguar Animal Health's insider trading history. Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Animal Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JAGX Stock News HeadlinesJaguar Health to participate in 2025 Animal Health SummitAugust 22, 2025 | msn.comJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of StockholdersAugust 20, 2025 | finanznachrichten.deREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 31 at 2:00 AM | Weiss Ratings (Ad)Jaguar Health Announces Promising Trial ResultsAugust 20, 2025 | msn.comJaguar Health, Inc. (JAGX) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | seekingalpha.comJaguar Health Reports Increased Losses Amid Rising ExpensesAugust 15, 2025 | msn.comJaguar Health Extends Market Offering AgreementAugust 14, 2025 | msn.comJaguar Health, Inc.: Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation Supports Research Efforts of Jaguar Health and ...July 8, 2025 | finanznachrichten.deSee More Headlines JAGX Stock Analysis - Frequently Asked Questions How have JAGX shares performed this year? Jaguar Animal Health's stock was trading at $25.25 at the start of the year. Since then, JAGX stock has decreased by 93.5% and is now trading at $1.63. How were Jaguar Animal Health's earnings last quarter? Jaguar Animal Health, Inc. (NASDAQ:JAGX) issued its quarterly earnings results on Thursday, August, 14th. The biotechnology company reported ($10.26) EPS for the quarter, missing analysts' consensus estimates of ($7.13) by $3.13. The biotechnology company had revenue of $2.98 million for the quarter, compared to analyst estimates of $3.27 million. Jaguar Animal Health had a negative net margin of 344.16% and a negative trailing twelve-month return on equity of 660.18%. Read the conference call transcript. When did Jaguar Animal Health's stock split? Jaguar Animal Health's stock reverse split on Thursday, May 23rd 2024.The 1-60 reverse split was announced on Thursday, May 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Jaguar Animal Health IPO? Jaguar Animal Health (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. How do I buy shares of Jaguar Animal Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jaguar Animal Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jaguar Animal Health investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Meta Platforms (META), Digital Turbine (APPS) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/14/2025Today8/31/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JAGX CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Jaguar Animal Health$60.00 High Price Target$60.00 Low Price Target$60.00 Potential Upside/Downside+3,581.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.49 million Net Margins-344.16% Pretax Margin-350.64% Return on Equity-660.18% Return on Assets-77.42% Debt Debt-to-Equity Ratio2.44 Current Ratio0.95 Quick Ratio0.59 Sales & Book Value Annual Sales$11.69 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book0.81Miscellaneous Outstanding Shares2,170,000Free Float2,076,000Market Cap$3.54 million OptionableNo Data Beta0.43 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:JAGX) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaguar Animal Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jaguar Animal Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.